Fujifilm expands gene therapy analytical services with $55m lab

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/undefined)
(Image: Getty/undefined)

Related tags: Fujifilm diosynth biotechnologies, Cell therapy, cell and gene therapy, Gene therapy, Process analytical technology

Fujifilm Diosynth opens a 60,000-square-feet Gene Therapy Innovation Center to support upstream, downstream and analytical development services.

The laboratory space will be added to Fujifilm Diosynth Biotechnologies (FDB) gene therapy manufacturing facility in Texas, US, and is expected to boost the company’s offering of process and analytical development services for gene therapies developers.

The establishment of the laboratory space, which will cost the company $55m (€49.65m), is part of a total investment of ¥13bn ($120m) made by Fujifilm Corporation, as part of the company’s effort to meet the growing demands of the market.

“We need to invest now, in technology, assets and people,” ​commented Martin Meeson, president and COO of FDB for the US, adding that the company is ‘very much aware’ of the gene therapy market’s ‘incredible’ growth.

The facility is expected to be operational in the fall of 2021 and will add approximately 100 jobs to the company’s College Station campus in Texas.

FDB’s 80,000-square-feet plant in Texas opened early last year​, with the company looking to tap into the booming cell and gene therapies space, and provide clinical and commercial manufacturing capabilities for developers.

Earlier this year, Meeson told us that the increase of assets has led the company to establish new partnerships, with interest continuously rising, and mentioned that, at that point, the Texas facility was ‘easily expandable’ to help the company answer such demand.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars